Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Eli Lillys Alimta (pemetrexed disodium) is a cytotoxic small molecule that has been approved in combination with cisplatin for the first-line treatment of locally-advanced and metastatic non-squamous NSCLC in the US, EU and Japan. It is also approved for use as a monotherapy in the maintenance and second-line settings in non-squamous patients.

Scope

Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Alimta including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Alimta for the top nine countries from 2012 to 2022.